United Kingdom

People: Editas Medicine Inc (EDIT.OQ)

EDIT.OQ on NASDAQ Stock Exchange Global Select Market

18 Jul 2019
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Vaishnaw, Akshay 

Dr. Akshay K. Vaishnaw is Independent Director of the Company. Dr. Vaishnaw has served as a member of our Board since July 2016. Dr. Vaishnaw has served as the President, Research and Development of Alnylam Pharmaceuticals, Inc. ("Alnylam"), which develops RNA-based therapies, since March 2018. Prior to that, Dr. Vaishnaw held a variety of positions at Alnylam, including Executive Vice President, Research and Development from December 2014 until March 2018, Chief Medical Officer from June 2011 until December 2016, Executive Vice President from June 2012 to December 2014, Senior Vice President from June 2011 to June 2012, Senior Vice President, Clinical Research from December 2008 to June 2011 and Vice President, Clinical Research from 2006 to 2008. From December 2014 until July 2018, Dr. Vaishnaw served as a director of Visterra, Inc., a private biopharmaceutical company focused on antibody-based therapies. From 1998 to 2005, Dr. Vaishnaw held various positions at Biogen. Dr. Vaishnaw is a Fellow of the Royal College of Physicians, United Kingdom. He received his M.D. from University of Wales College of Medicine and his Ph.D. from the University of London. We believe Dr. Vaishnaw's qualifications to sit on our Board include his strong medical background and experience as an executive at biopharmaceutical companies.

Basic Compensation

Total Annual Compensation, USD 46,539
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 302,956
Fiscal Year Total, USD 349,495

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

James Mullen


Cynthia Collins


Eric Ek


Vickesh Myer


Charles Albright


Katrine Bosley

As Of  31 Dec 2018